Key result
Prednisolone added to antituberculosis chemotherapy reduced the overall death rate (p=0.044) and risk of death from pericarditis (p=0.004) over 10 years in patients with tuberculous pericarditis.
Why the study?
Does prednisolone and/or open drainage reduce adverse outcomes in patients with tuberculous pericarditis at 10 years?
RCT (n=383)
Double-blind
randomized
Does prednisolone and/or open drainage reduce adverse outcomes in patients with tuberculous pericarditis at 10 years?
Absolute Event Rate: 27% vs 38%
p-value: p=0.15
Prednisolone added to anti-tuberculosis chemotherapy provides sustained long-term reduction in pericarditis-related mortality at 10 years in patients with tuberculous pericarditis.
No takes yet. Share an insight, caveat, or question.
Supports adjunctive prednisolone in tuberculous pericarditis; extends RCT evidence to sustained 10-year survival benefit.
Strang et al. (2004) conducted an RCT in Tuberculous constrictive pericarditis and tuberculous pericardial effusion (n=383). Prednisolone and/or open surgical drainage vs. Placebo and/or pericardiocentesis was evaluated on Adverse outcomes (death from pericarditis, pericardiectomy, repeat pericardiocentesis, and subsequent open drainage) (p=0.15). Prednisolone added to antituberculosis chemotherapy reduced the overall death rate (p=0.044) and risk of death from pericarditis (p=0.004) over 10 years in patients with tuberculous pericarditis.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: